Skip to content
Screener

Jazz Pharmaceuticals JAZZ Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Amgen logo
AmgenAMGN
$0—
Exelixis logo
ExelixisEXEL
$798K-71.2%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.65B+148%
Enterprise value$21.39B+95.4%
P/S3.8×+2.1×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueCash and Cash EquivalentsInvestments
Cash$667.5——$667.5$667.5—
Time deposits1,090.0——1,090.060.01,030.0
Money market funds1,116.8——1,116.81,116.8—
Totals$2,874.3——$2,874.3$1,844.3$1,030.0

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's unrealized gains on investments?
Jazz Pharmaceuticals (JAZZ) reported unrealized gains on investments of $0 in Q1 2026.

Ask your AI about Jazz Pharmaceuticals's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude